The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy
Polycystic ovary syndrome is a highly frequent reproductive-endocrine disorder affecting up to 8–10% of women worldwide at reproductive age. Although its etiology is not fully understood, evidence suggests that insulin resistance, with or without compensatory hyperinsulinemia, and hyperandrogenism a...
Saved in:
Main Authors: | Eduardo Spinedi, Daniel P. Cardinali |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2018/1349868 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Diagnosis and treatment of polycystic ovary syndrome
by: Ronelsys Martínez Martínez, et al.
Published: (2023-11-01) -
Expression of SET Protein in the Ovaries of Patients with Polycystic Ovary Syndrome
by: Xu Boqun, et al.
Published: (2013-01-01) -
Mitochondrial DNA oxidation and content in different metabolic phenotypes of women with polycystic ovary syndrome
by: Mailén Rojo, et al.
Published: (2025-01-01) -
The role of diet therapy in insulin resistance in women with polycystic ovary syndrome
by: H.B. Semenyna, et al.
Published: (2025-01-01) -
New biomarkers for diagnosis of polycystic ovary syndrome
by: Farid I. Hassan, et al.
Published: (2023-04-01)